Recent patents in antiviral siRNAs

Recent Patents on Anti-Infective Drug Discovery

Volumn 5, Issue 1, 2010, Pages 44-57

  Saravolac, Edward G ^a   Wong, Jonathan P ^b   Cairns, Murray J ^c,d  

^a Formulation Technology Consulting   (Australia)

^b DEFENCE RESEARCH AND DEVELOPMENT CANADA   (Canada)

^c SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

Antiviral prophylaxis; Antiviral therapeutics; Patents; Small interfering RNA; Virus infection

Indexed keywords

ADEFOVIR; ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTIVIRUS AGENT; APTAMER; CHITOSAN; CHOLESTEROL; CISPLATIN; DENDRIMER; LAMIVUDINE; LENTIVIRUS VECTOR; LIPOSOME; MACROGOL; MICRORNA; MIR 17 92; NANOPARTICLE; NUCLEIC ACID; NUCLEOPROTEIN; OLIGORIBONUCLEOTIDE; PARVOVIRUS VECTOR; POLYAMIDE; POLYAMIDOAMINE; POLYAMINOACID; POLYETHYLENEIMINE; POLYLYSINE; POLYMER; POLYNUCLEOTIDE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CISTRON; DRUG CONJUGATION; DRUG MECHANISM; DRUG TARGETING; GENE SILENCING; HEPATITIS B; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFLUENZA; MICELLE; MOLONEY LEUKEMIA ONCOVIRUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA INTERFERENCE; RNA SYNTHESIS; UTERINE CERVIX CANCER; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION;

ANIMALS; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; PATENTS AS TOPIC; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS DISEASES;

EID: 77953758476     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489110790112590     Document Type: Article

References (151)

1. Saravolac EG, Wong JP. Recent patents on development of nucleic acid based antiviral drugs against seasonal and pandemic influenza virus infections. Recent Pat Anti-Infect Drug Discov 2007; 3:140-147.
2. Fire A, Xu S, Montgomery M, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811.
3. Elbashir SM, Halborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-498.
4. ter Brake O, Haasnoot J, Kurreck J, Berkhout B. ESF-EMBO Symposium: Antiviral applications of RNA interference. Retrovirol 2008; 5: 81.
5. Molnar A, Csorba T, Lakatos L, et al. Plant virus-derived small interfering RNAs originated predominately from highly structured singe-stranded viral RNAs. J Virol 2005; 79: 7812-7818.
6. Wasseneggger M, Krczal G. Nomenclature and functions of RNA-directed RNA polymerases. Trends Plant Sci 2006; 11:142-151.
7. Sarbah SA, Younossi, ZM. Hepatitis C: An update on the silent epidemic. J Clin Gastroenterol 2000; 30:125-143.
8. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-1745.
9. Markowitz LE, Dunne EF, Saraiya M, et al. Quadravalent human papillomavirus vaccine: Recommendations of the advisory committee on immunization practices (AICP). MMWR Recom Rep 2007; 56:1-24.
10. Lipsitch ML, Riley S, Causchmez S, et al. Managing and reducing uncertainty in an emerging influenza pandemic. New Engl J Med 2009; 361:112-115.
11. Chen Y, Cheng G. Mahato RI. RNAi for treating hepatitis B viral infection. Pharm Res 2008; 35: 72-85.
12. Pal, B.K., Tran, L.M.: US20077100109 (2007).
13. Pal, B.K., Tran, L.M.: US20077288531 (2007).
14. Pal, B.K., Tran, L.M.: US20077304042 (2007).
15. Chen, J., Eisen, H.N., Ge, Q.: US20040242518 (2004).
16. Lam, E., Poon L.M., Zhou, Y., Chye, M.L., Peiris, J.S.M.: US20060282921 (2006).
17. Jadhav, V., Robin, H., McSwiggen, J.: US20070099858 (2007).
18. McSwiggen, J.A., Ge, Q.: US20070213293 (2007).
19. MacLachlan, I., Robbins, M.: US20070218122 (2007).
20. Tang, Q., Lu, P.Y., Xie, F.Y., Woodle, M.C., Zheng, B.: US20080279920 (2008).
21. Kung, H.-F., He, M.-L.: US20067067249 (2006).
22. Kim, M., Duckhyang, D., Kim, S.I., Park, M.: US20080096839 (2008).
23. Jayasena, S., Richardson, C.D.: WO2005012525 (2005).
24. Kim, M., Duckhyang, D., Park, M.: WO2006129961 (2006).
25. Kaspar, R.L., Ilves, H., Seyhan, A.A., Johnston, B.H.: US20070149470 (2007).
26. McSwiggen, J., Morrissey, D., Guerciolini R.: US20060211642 (2006).
27. Luo, G.: WO2008021353 (2008).
28. Li, Y.: WO2005012483 (2005).
29. Qin, X.-F., Baltimore, D.: US20077195916 (2007).
30. Qin, X.-F., Baltimore, D., Chen, I.S.Y., An, D.S.: US20080003658 (2008).
31. Thompson, J.E., Taylor, C., Dinarello, C.A., Donero, R.S.: US20070238691 (2007).
32. Rossi, J.J., Zhou, J.: US20090148944 (2009).
33. McSwiggen, J., Beigelman, L., Macejak, D.: US20050191618 (2005).
34. Mohapatra, S., Zhang, W.: WO2005056021 (2005).
35. Tang, Q., Lu, P.Y., Xie, F.Y., Woodle, M.C., Zheng, B.: US20080279920 (2008).
36. Viash, N.K., Vargeese, C., McSwiggen, J.: US20060287267 (2006).
37. Lieberman, J., Palliser, D., Knipe, D.: WO2006133099 (2006).
38. Yoshinouchi, M., Yamato, K.: WO2006035974 (2006).
39. Shin, Y.K., Jung, H.S., Oh, Y.K.: WO2008054184 (2008).
40. McSwiggen, J., Bharat, C., Haeberli, R.: WO2004092383 (2004).
41. Tang, Q.T., Lu, P.Y., Xie, F.Y., Liu, Y., Xu, J., Woodle, M.C.: US20070203082 (2007).
42. Karlas, A., Denner, J., Kurth, R.: EP1582591 (2005).
43. Fauquet, C.M., Padmanabhan, C., Ramachandran, V.: US20040261149 (2004).
44. Yen, H.-H., Chen, H.-H., Lu, S.-J.: US20070220633 (2007).
45. von Eije KJ, Berkhout B. RNA-interference based gene therapy approaches to HIV type-1 treatment: Tackling the hurdles from bench to bedside. Antivirus Chem Chemother 2009; 19: 221-223.
46. Trifonov V, Khiabanian H, Rabadan P. Geographic dependance, survalence and origins of the 2009 influenza A (H1N1) virus. N Engl J Med 2009; 361:115-119.
47. World Health Organization. Influenza: Report by the secretariat to the fifty-sixth world health assembly. WHO Geneva, A56/23, 2003.
48. McSwiggen JA, Seth S. A potential treatment for pandemic influenza using siRNAs targeting conserved regions of influenza A. Expert Opin Biol Ther 2008; 8: 299-313.
49. Zhou K, He H, Wu Y, Duan M. RNA Interference of avian influenza virus H5N1 by inhibiting viral mRNA with siRNA expression plasmids. J Biotechnol 2008; 135:140-144.
50. Robbins M, Judge A, Ambegia E, et al. Misinterpreting the therapeutic effects of siRNA caused by immune stimulation. Hum Gene Ther 2008; 19: 991-999.
51. Karayiannis P. Hepatitis B virus: Old, new and future approaches to antiviral treatment. J Antimicrob Chemother 2003; 51:761-785.
52. Pan Q, Tilanus HW, Janssen HLA, van der Laan LJW Prospects of RNAi and microRNA based therapies for hepatitis C. Expert Opin Biol Ther 2009; 9:713-724.
53. Zhu Q, Oei Y, Mendel DB, et al. Novel robust Hepatitis C virus mouse efficacy model. Anti Microb Agents Chemother 2006; 50:3260-3268.
54. Icard V, Diaz O, Perrin-Cocon L, et al. Secretion of hepatitis C virus envelope glycoproteins depends upon assembly of apolipoprotein B positive lipoproteins. PLoS ONE 2009; 4: e4233.
55. Chang K-S, Jiang J, Cai Z, Luo G. Human apolipoprotein E is required for infectivity and production of hepatitis C virus in Cell Culture. J Virol 2007; 81:13783-13793.
56. Gao Y, Lobritz MA, Roth J, et al. Targets of interfering RNA restriction during human immunodeficiency virus type I replication. J Virol 2008; 82:2938-2951.
57. Zhang W, Tripp RA. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J Virol 2008; 82: 12221-12231.
58. Wald A. Clinical evidence genital herpes. West J Med 1999; 170: 343-346.
59. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Org 2008; 86:805-813.
60. Putral LN, Bywater MJ, Gu W, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in reduced sensitivity to cisplatin. Mol Pharmacol 2005; 68: 1311-1319.
61. Ferlay J, Bray FP, Pisani P, Parkin DM. Globocan 2002: Cancer incidence, mortality and prevalence worldwide. IARC Press: Lyon, France 2004.
62. Tang Q, Li B, Woodle M, Lu PY. Application of siRNA against SARS in the Rhesus macaque model. Methods Mol Biol 2008; 442:139-158.
63. Reischl D, Zimmer A. Drug delivery of siRNA therapeutics: Potentials and limits of nanosystems. Nanomedicine 2009; 5: 8-20.
64. Tan ML, Choong, PF, Dass CR. DNAzyme delivery systems: Getting past first base. Expert Opin Drug Deliv 2009; 6:127-138.
65. Yee JK, Burns JC, Friedmann T, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: Concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90: 8033-8037.
66. Burns, J.C., Yee, J.-K., Friedmann, T.: US5512421 (1996).
67. Miller DG, Adam, MA, Miller AD, et al. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10: 4239-4242.
68. Vigna E, Naldini L. Lentiviral vectors: Excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308-316.
69. Naldini L, Bloomer U, Kafri T, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a leniviral vector. Proc Natl Acad Sci USA 1996; 20:11382-11388.
70. Kafri, T, Blomer U, Peterson FH, et al. Sustained expression of gene delivered directly into liver an muscle by leiviral vectors. Nat Genet 1997; 17:314-317.
71. Bloomer U, Naldini L, Kafri T, et al. Highly efficient and sustained gene trasfer in adult neurons with a leivirus vector. J Virol 1997; 71: 6641-6639.
72. Emi N, Friedmann T, Yee JK, et al. Pseudotype formation of murine leukemis virus with the G protein of vesicular stomatitis virus. J Virol 1991; 65:1202-1207.
73. Schauber CA, Tuerk MJ, Pacheco CD, et al. Lentiviral vectors pseudotyped with baculovirus gp64 efficiently transduce mouse cells in vivo and show tropism restriction against hematopoietic cells in vitro. Gene Ther 2004; 11: 266-275.
74. Schauber, C.A., Pacheco, C.D.: US20056863884 (2005).
75. Hofmann C, Sandig V, Kirillowa I, et al. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci USA 1995; 92:10099-10103.
76. Boyce FM, Bucher NL. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci USA 1996; 93: 2348-2352.
77. Condreay PP, Witherspoon SM, Clay WC, et al. Transient and stable gene expression in mammalian cells transduced with a recombinant vaculovirus vector. Proc Natl Acad Sci USA 1999; 96: 127-132.
78. Yang L, Bailey L, Baltimore D, et al. Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci USA 2006; 103: 11479-11484.
79. Wang, P., Yang, L., Baltimore, D.: WO2006130855 (2006).
80. Li H, Murphy SL, Giles-Davis W, et al. Pre-exisiting AAV capsidspecific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther 2007; 15:792-800.
81. Duan D, Sharma P, Yang J, et al. Circular intermediates of recombinant adenoassociated virus have defined structrual characteristics responsible for long-term episomal persistance in muscle tissue. J Virol 1991; 65:1202-1207.
82. Hildinger, M., Auricchio, A.: US20050019927 (2005).
83. Brummelkamp TR, Bernards R, Agami R, et al. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
84. Paul CP, Good PD, Winer L, et al. Effective expression of small interfering RNA in human cells. Nat Biotech 2002; 505-508.
85. Agami, R., Brummelkamp, T.: US20077241618 (2007).
86. Engelke, D.R., Good, P.D., Paul, C.D.: US20030148519 (2003).
87. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 2006; 441: 537-541.
88. Giering JC, Grimm D, Storm TA, et al. Expression of shRNA from a tissue-specific pol II promoter is an effective and safe RNAi therapeutic. Mol Ther 2008; 16:1630-1636.
89. Roelvink, P.W., Suhy, D.A., Kolykhalov A.A., Kay, M.A., Giering, J.C.: US20060189561 (2006).
90. Davidson, B.L., Xia, H., Mao, Q.: US20040023390 (2004).
91. Stegmeier F, Hu G, Rickles RJ, et al. A lentiviral microRNA-based system for single-copy polymerase II regulated RNA interference in mammalian cells. Proc Natl Acad Sci USA 2005; 102:13212-13217.
92. Dickins, R., Hannon, G.L., Lowe, S.W.: US20070044164 (2007).
93. Boden D, Pusch O, Silbermann R, et al. Enhance gene silencing of HIV-1 specific siRNA using microRNA designed hairpins. Nucleic Acids Res 2004; 32: 1154-1158.
94. Tran N, Cairns MJ, Arndt GM, et al. Expressing functional siRNAs in mammalian cells using convergent transcription. BMC Biotechnol 2003; 3: 21.
95. Kaykas A, Moon RT. A plasmid-based system for expressing small interfering RNA libraries in mammalian cells. BMC Cell Biol 2004; 5: 16.
96. Arndt, G.M., Cairns, M.J., Tran, N., Lai, A.: WO2004022777 (2004).
97. Kaykas, A., Moon, R.T.: US20050233994 (2005).
98. Lai A, Cairns MJ, Tran N, et al. RNA modulators of complex phenotypes in mammalian cells. PLoS One 2009; 4: e4758.
99. Liu YP, Haasnoot J, Gruber J, et al. design of extended short hairpin RNAs for HIV-1 inhibition. Nucleic Acids Res 2007; 35: 5683-5693.
100. Song J, Giang A, Lu Y, et al. Multiple shRNA expressing vector enhances efficiency of gene silencing. BMB Rep 2008; 41:358-362.
101. Chiu, R.H., Song, J.: WO2007124452 (2007).
102. Morris KV, Rossi JJ. Lentivirus-mediated RNA interference therapy for human immunodeficiency virus type 1 infection. Hum Gene Ther 2006; 17: 479-486.
103. Akashi H, Miyagishi M, Yokota T, et al. Escape from the interferon response associated with RNA interference using vectors that encode long modified hairpin-RNA. Mol Biosyst 2005; 1: 382-390.
104. Aagaard LA, Zhang J, von Eije KJ, et al. Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther 2008; 15: 1536-1549.
105. Liu YP, Haasnoot J, ter Brake O, et al. Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 2008; 36: 2811-2824.
106. Lewis, D.L., Hagstrom, J.E., Herweijer, H., Loomis, A.G., Monaham, S.D., Wolff, J.A.: US20067101995 (2006).
107. Artursson, P.A.S., Issa, M.M., Strand, S.P., Varum, K.M.: US20080131371 (2008).
108. Yu, L., Zhao, G., Ma, N., Zhao, X., Liu, J., Tanaka, Y.: US20080312174 (2008).
109. Hirt, T., Lu, Z.: US20080312134 (2008).
110. Jeong, J.H., Park, T.G., Kim, S.-H.: US20070287681 (2007).
111. Kim, W.J., Kim, S.W.: US20070207966 (2007).
112. Triche, T.J., Hu, S.: US20070202076 (2007).
113. Burkoth, T.S., Jefferson, A.B., Reinhard, C., Zuckermann, R.N.: US20060019912 (2006).
114. Tewari, M., Kim, Y., Discher, D.: WO2008060557 (2008).
115. Peer, D., Shimaoka, M.: WO2007127221 (2007).
116. Sullenger, B.A.: WO2007143086 (2007).
117. Rana, T.M.: WO2007089607 (2007).
118. Vargeese, C., Weimin, W., Chen, T., Sweedler, D., Haeberli, P.: WO2005007854 (2005).
119. Trubetskov, V.S., Monahan, S.D., Budker, V.G., Wolff, J.A., Slattum, P.M.: WO2004076674 (2004).
120. Keller, M., Jorgensen, M., Miller, A.D., Perouzel, E.: US20080063701 (2008).
121. Chen, T., Vargesse, C., Vagle, K., Wang, W., Zhang, Y.: US20060240554 (2006).
122. MacLachlan, I., Ambegia, E.G., Heyes, J.: US20050064595 (2005).
123. Merritt, W.K., Sood, A.K., Bar-Eli, M., Lopez-Berestein, G.: WO2008109432 (2008).
124. Radovic, M.A.F., Zhang, L., Langer, R.S.: WO2008124634 (2008).
125. Sood, A.K., Lopez-Berestein, G., Landen, C.N., Chaves-Reyes, A.: WO2006113679 (2006).
126. Ahmad, M.U., Sheikh, S., Ali, S, Chien, P.-Y., Jamil, H., Zhang, J-A, Ugwu, S., Zhang, Z.-Y., Wang, J., Bhamidipati, S., Ahman, Z., Ahmad, I.: WO2005067632 (2005).
127. Han, J., Houghton, M.: US20080269148 (2008).
128. Ahmadian, M., Cui, K., Chen, C., Houston, M.E.: WO2006019430 (2006).
129. Rana, T.M.: US20040204377 (2004).
130. Zon, G.: WO2007087544 (2007).
131. Rademacher, T.M., Gumaa, K., Martin-Lomas, M., Penades, S., Ojeda, R., Barrientes, A.G.: WO2005116226 (2006).
132. Vargeese, C., Haeberli, P., Wang, W., Chen, T.: WO2005041859 (2005).
133. Wu, T.-C., Hung, C.-F.: US20080069840 (2008).
134. Ashton, P.: US20050163844 (2005).
135. Hagstrom, J.E., Wolff, J.A., Monahan, S.D., Rozema, D.B., Budker, V.G., Slattum, P.M., Lewis, D.L.: US20040106567 (2004).
136. Sen, L.: WO2008112787 (2008).
137. Urban-Klein B, Werth S, Abuharbeid S, Czubayko F, Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 2005; 12: 461-466.
138. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs agains a lethal Ebola virus challenge is confirred by RNA interference. J Infec Dis 2006; 193: 1650-1657.
139. Li W, Szoka FC Jr. Lipid-based nanoparticles for nucleic acid delivery. Pharm Res 2007; 24: 438-449.
140. Caroma S, Jorgensen MR, Kolli S, et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol Pharmacol 2009; 6: 706-717.
141. Semple SC, Klimuk SK, Harasym TO, Hope MJ. Lipid based formulations of antisense oligonucleotides for systemic delivery applications. Methods Enzymol 2000; 313: 322-341.
142. Corey DR. Chemical modification: The key to clinical application of RNA interference? J Clin Invest 2007; 117: 3615-3622.
143. Bramsen JB, Laursen MB, Nielsen AF, et al. A large scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res 2009; 37: 2681-2687.
144. Schiffelers RM, Xu J, Storm G, et al. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced artritis. Arthritis Rheum 2005; 52: 1314-1318.
145. Bonetta L. RNA-based therapeutics: Ready for delivery. Cell 2009; 136: 581-584.
146. Mitsuyasu RT, Merigan TC, Carr A, et al. Phase 2 gene therapy trial of an anit-HIV ribozyme in autologous CD34+ cells. Nat Med 2009; 15: 285-292.
147. Li M, Rossi JJ. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol Biol 2008; 433: 287-299.
148. Mangala LS, Zuzel V, Schmandt R, et al. Therapeutic targeting of ATP7B ovarian carcinoma. Clin Cancer Res 2009; 15: 3770-3780.
149. Helzner J. OPKO terminates wet AMD trial. Retinal Phys 2009.[on line]
150. Zang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2009; 359: 1456-1463.
151. DeVincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008; 77: 225-231.